We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Groundbreaking Rheumatoid Arthritis Blood Test Predicts Treatment Response

By LabMedica International staff writers
Posted on 30 Nov 2023
Print article
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)

Rheumatoid arthritis (RA), an autoimmune disease affecting joints and other systems in the body, impacts millions globally. Typically, the initial biologic treatment involves anti-inflammatory drugs from the tumor necrosis factor inhibitor (TNFi) family, including FDA-approved Infliximab and Adalimumab. However, only about 30% of RA patients find success with TNFi treatment after six months. This delay in identifying ineffective treatments can be costly, as RA can progress to cause irreversible bone damage. Now, a new predictive blood test promises to revolutionize treatment by guiding doctors to the most effective therapies for individual RA patients.

The PrismRA blood test from Scipher Medicine (Waltham, MA, USA), a Northeastern University (Boston, MA, USA) spinoff, is the first clinically validated RA test that predicts treatment response. Marking a significant step forward in RA treatment, the test is capable of determining the suitability of TNFi treatments for RA patients before they begin therapy. This is particularly beneficial as TNFis are also used in treating other immune-mediated conditions like inflammatory bowel disease and psoriasis.

Scipher researchers recognized the urgent need to identify responders and non-responders to TNFis from the outset of treatment. They utilized publicly available datasets and obtained baseline blood data and TNFi response rates from hundreds of RA patients. Through this data, they applied machine-learning algorithms to predict TNFi treatment efficacy using genetic markers in the blood. Further validation was achieved by enrolling around 700 RA patients in a prospective trial to assess the test's clinical utility. The trial's findings were encouraging; patients using the PrismRA biomarker test for guiding therapy were three times more likely to achieve remission compared to those who didn’t.

The PrismRA testing process involves a simple blood draw at a doctor’s office, followed by RNA sequencing analysis. Scipher’s PrismRA test then predicts the likelihood of a patient not responding to TNFis. Based on these results, physicians can decide on an alternative therapy for the patient. With the development of this biologic test, the focus now shifts to creating similar blood marker tests for other autoimmune diseases. Scipher’s extensive collection of whole blood RNA-seq data from over 20,000 patients offers a robust molecular database for future research and test development.

“This is the first clinically validated rheumatoid arthritis test that predicts treatment response,” said Northeastern graduate Susan Dina Ghiassian, who was the first employee of Scipher Medicine. “Patients will get a chance to be put on the right therapy from day one.”

Related Links:
Scipher Medicine 
Northeastern University 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article



view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more


view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more


view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.